{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T07:07:07Z","timestamp":1793862427517,"version":"4.6.1"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"23","license":[{"start":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T00:00:00Z","timestamp":1649376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,6,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Heart failure (HF) is a global challenge, with lower- and middle-income countries (LMICs) carrying a large share of the burden. Treatment for HF with reduced ejection fraction (HFrEF) improves survival but is often underused. Economic factors might have an important effect on the use of medicines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>This analysis assessed prescription rates and doses of renin\u2013angiotensin system (RAS) inhibitors, \u03b2-blockers, and mineralocorticoid receptor antagonists at discharge and 6-month follow-up in 8669 patients with HFrEF (1458 from low-, 3363 from middle-, and 3848 from high-income countries) hospitalized for acute HF in 44 countries in the prospective REPORT-HF study. We investigated determinants of guideline-recommended treatments and their association with 1-year mortality, correcting for treatment indication bias.<\/jats:p>\n                    <jats:p>Only 37% of patients at discharge and 34% of survivors at 6 months were on all three medication classes, with lower proportions in LMICs than high-income countries (19 vs. 41% at discharge and 15 vs. 37% at 6 months). Women and patients without health insurance, or from LMICs, or without a scheduled medical follow-up within 6 months of discharge were least likely to be on guideline-recommended medical therapy at target doses, independent of confounders. Being on \u226550% of guideline-recommended doses of RAS inhibitors, and \u03b2-blockers were independently associated with better 1-year survival, regardless of country income level.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Patients with HFrEF in LMICs are less likely to receive guideline-recommended drugs at target doses. Improved access to medications and medical care could reduce international disparities in outcome.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehac103","type":"journal-article","created":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T07:08:32Z","timestamp":1645513712000},"page":"2224-2234","source":"Crossref","is-referenced-by-count":62,"title":["Global disparities in prescription of guideline-recommended drugs for heart failure with reduced ejection fraction"],"prefix":"10.1093","volume":"43","author":[{"given":"Jasper","family":"Tromp","sequence":"first","affiliation":[{"name":"Saw Swee Hock School of Public Health, National University of Singapore & National University Health System , Singapore"},{"name":"Duke-National University of Singapore Medical School , Singapore"},{"name":"Department of Cardiology, University Medical Centre Groningen, University of Groningen , Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2000-9358","authenticated-orcid":false,"given":"Wouter","family":"Ouwerkerk","sequence":"additional","affiliation":[{"name":"National Heart Centre Singapore , 5 Hospital Dr, Singapore 169609 , Singapore"},{"name":"Department of Dermatology, University of Amsterdam Medical Centre , Amsterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiew-Hwa K","family":"Teng","sequence":"additional","affiliation":[{"name":"Duke-National University of Singapore Medical School , Singapore"},{"name":"National Heart Centre Singapore , 5 Hospital Dr, Singapore 169609 , Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1471-7016","authenticated-orcid":false,"given":"John G F","family":"Cleland","sequence":"additional","affiliation":[{"name":"Robertson Centre for Biostatistics and Clinical Trials, Institute of Health & Well-Being, University of Glasgow and National Heart & Lung Institute, Imperial College , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahiddah","family":"Bamadhaj","sequence":"additional","affiliation":[{"name":"National Heart Centre Singapore , 5 Hospital Dr, Singapore 169609 , Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7491-7637","authenticated-orcid":false,"given":"Christiane E","family":"Angermann","sequence":"additional","affiliation":[{"name":"Department of Medicine I and Comprehensive Heart Failure Center, University Hospital W\u00fcrzburg , W\u00fcrzburg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6353-8041","authenticated-orcid":false,"given":"Ulf","family":"Dahlstrom","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Linkoping University , Linkoping , Sweden"},{"name":"Department of Health, Medicine and Caring Sciences, Linkoping University , Linkoping , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2397-5946","authenticated-orcid":false,"given":"Wan Ting","family":"Tay","sequence":"additional","affiliation":[{"name":"National Heart Centre Singapore , 5 Hospital Dr, Singapore 169609 , Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Dickstein","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University of Bergen, Stavanger University Hospital , Stavanger , Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Ertl","sequence":"additional","affiliation":[{"name":"Department of Medicine I and Comprehensive Heart Failure Center, University Hospital W\u00fcrzburg , W\u00fcrzburg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Hassanein","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Cardiology Department Alexandria, Alexandria University , Alexandria , Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio V","family":"Perrone","sequence":"additional","affiliation":[{"name":"El Cruce Hospital by Florencio Varela, Lezica Cardiovascular Institute, Sanctuary of the Trinidad Miter , Buenos Aires , Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3608-7625","authenticated-orcid":false,"given":"Mathieu","family":"Ghadanfar","sequence":"additional","affiliation":[{"name":"M-Ghadanfar Consulting (Life Sciences) , Basel , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8787-3442","authenticated-orcid":false,"given":"Anja","family":"Schweizer","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG , Basel , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achim","family":"Obergfell","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG , Basel , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean P","family":"Collins","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Vanderbilt University Medical Center , Nashville, TN , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5640-0332","authenticated-orcid":false,"given":"Gerasimos","family":"Filippatos","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University of Cyprus, School of Medicine & National and Kapodistrian University of Athens, School of Medicine, Attikon University Hospital , Athens , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1903-0018","authenticated-orcid":false,"given":"Carolyn S P","family":"Lam","sequence":"additional","affiliation":[{"name":"Duke-National University of Singapore Medical School , Singapore"},{"name":"Department of Cardiology, University Medical Centre Groningen, University of Groningen , Groningen , The Netherlands"},{"name":"National Heart Centre Singapore , 5 Hospital Dr, Singapore 169609 , Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,4,8]]},"reference":[{"key":"2022102605495389800_ehac103-B1","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1056\/NEJMoa052256","article-title":"Trends in prevalence and outcome of heart failure with preserved ejection fraction","volume":"355","author":"Owan","year":"2006","journal-title":"N Engl J Med"},{"key":"2022102605495389800_ehac103-B2","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1161\/01.CIR.0000039105.49749.6F","article-title":"Lifetime risk for developing congestive heart failure: The Framingham Heart Study","volume":"106","author":"Lloyd-Jones","year":"2002","journal-title":"Circulation"},{"key":"2022102605495389800_ehac103-B3","doi-asserted-by":"crossref","first-page":"e665","DOI":"10.1016\/S2214-109X(17)30196-1","article-title":"Global mortality variations in patients with heart failure: results from the International Congestive Heart Failure (INTER-CHF) prospective cohort study","volume":"5","author":"Dokainish","year":"2017","journal-title":"Lancet Glob Health"},{"key":"2022102605495389800_ehac103-B4","doi-asserted-by":"crossref","first-page":"e411","DOI":"10.1016\/S2214-109X(20)30004-8","article-title":"Post-discharge prognosis of patients admitted to hospital for heart failure by world region, and national level of income and income disparity (REPORT-HF): a cohort study","volume":"8","author":"Tromp","year":"2020","journal-title":"Lancet Glob Health"},{"key":"2022102605495389800_ehac103-B5","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"2022102605495389800_ehac103-B6","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1161\/CIR.0000000000000509","article-title":"2017 ACC\/AHA\/HFSA Focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines and the Heart Failure Society of America","volume":"136","author":"Yancy","year":"2017","journal-title":"Circulation"},{"key":"2022102605495389800_ehac103-B7","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"SOLVD Investigators","year":"1991","journal-title":"N Engl J Med"},{"key":"2022102605495389800_ehac103-B8","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)","volume":"316","author":"CONSENSUS Trial Study Group","year":"1987","journal-title":"N Engl J Med"},{"key":"2022102605495389800_ehac103-B9","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-added trial","volume":"362","author":"McMurray","year":"2003","journal-title":"Lancet"},{"key":"2022102605495389800_ehac103-B10","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-alternative trial","volume":"362","author":"Granger","year":"2003","journal-title":"Lancet"},{"key":"2022102605495389800_ehac103-B11","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","article-title":"The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial","volume":"353","author":"CIBIS-II Investigators and Committees","year":"1999","journal-title":"Lancet"},{"key":"2022102605495389800_ehac103-B12","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"2022102605495389800_ehac103-B13","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"2022102605495389800_ehac103-B14","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"2022102605495389800_ehac103-B15","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin\u2013neprilysin inhibition in acute decompensated heart failure","volume":"380","author":"Velazquez","year":"2019","journal-title":"N Engl J Med"},{"key":"2022102605495389800_ehac103-B16","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jacc.2018.04.070","article-title":"Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry","volume":"72","author":"Greene","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2022102605495389800_ehac103-B17","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1093\/eurheartj\/ehx026","article-title":"Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study","volume":"38","author":"Ouwerkerk","year":"2017","journal-title":"Eur Heart J"},{"key":"2022102605495389800_ehac103-B18","doi-asserted-by":"crossref","first-page":"e1008","DOI":"10.1016\/S2214-109X(18)30306-1","article-title":"Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study","volume":"6","author":"Teng","year":"2018","journal-title":"Lancet Glob Health"},{"key":"2022102605495389800_ehac103-B19","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1002\/ejhf.887","article-title":"Physicians\u2019 guideline adherence is associated with better prognosis in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry","volume":"19","author":"Komajda","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2022102605495389800_ehac103-B20","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/ejhf.262","article-title":"International REgistry to assess medical Practice with lOngitudinal obseRvation for Treatment of Heart Failure (REPORT-HF): rationale for and design of a global registry","volume":"17","author":"Filippatos","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"2022102605495389800_ehac103-B21","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1001\/jamacardio.2019.5108","article-title":"Global differences in characteristics, precipitants, and initial management of patients presenting with acute heart failure","volume":"5","author":"Filippatos","year":"2020","journal-title":"JAMA Cardiol"},{"key":"2022102605495389800_ehac103-B22","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jchf.2020.12.015","article-title":"Global differences in burden and treatment of ischemic heart disease in acute heart failure: REPORT-HF","volume":"9","author":"Tromp","year":"2021","journal-title":"JACC Heart Fail"},{"key":"2022102605495389800_ehac103-B23","first-page":"1","volume-title":"World bank Country and lending groups\u2014World bank data help desk","author":"World Bank","year":"2017"},{"key":"2022102605495389800_ehac103-B24","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1016\/j.jacc.2019.02.015","article-title":"Titration of medical therapy for heart failure with reduced ejection fraction","volume":"73","author":"Greene","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2022102605495389800_ehac103-B25","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.ahj.2011.01.027","article-title":"Potential impact of optimal implementation of evidence-based heart failure therapies on mortality","volume":"161","author":"Fonarow","year":"2011","journal-title":"Am Heart J"},{"key":"2022102605495389800_ehac103-B26","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1002\/ejhf.1234","article-title":"Incremental benefit of drug therapies for chronic heart failure with reduced ejection fraction: a network meta-analysis","volume":"20","author":"Komajda","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2022102605495389800_ehac103-B27","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1093\/eurheartj\/ehaa071","article-title":"The association of long-term outcome and biological sex in patients with acute heart failure from different geographic regions","volume":"41","author":"Motiejunaite","year":"2020","journal-title":"Eur Heart J"},{"key":"2022102605495389800_ehac103-B28","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jchf.2020.08.017","article-title":"Heart failure hospitalization and guideline-directed prescribing patterns among heart failure with reduced ejection fraction patients","volume":"9","author":"Srivastava","year":"2021","journal-title":"JACC Heart Fail"},{"key":"2022102605495389800_ehac103-B29","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/ejhf.510","article-title":"Physicians\u2019 adherence to guideline-recommended medications in heart failure with reduced ejection fraction: data from the QUALIFY global survey","volume":"18","author":"Komajda","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2022102605495389800_ehac103-B30","doi-asserted-by":"crossref","first-page":"e001718","DOI":"10.1161\/JAHA.114.001718","article-title":"National quality assessment evaluating spironolactone use during hospitalization for acute myocardial infarction (AMI) in China: China Patient-centered Evaluation Assessment of Cardiac Events (PEACE)-retrospective AMI study, 2001, 2006, and 2011","volume":"4","author":"Guan","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"2022102605495389800_ehac103-B31","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1161\/01.HYP.0000259805.18468.8c","article-title":"Effect of spironolactone on blood pressure in subjects with resistant hypertension","volume":"49","author":"Chapman","year":"2007","journal-title":"Hypertension"},{"key":"2022102605495389800_ehac103-B32","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1002\/ejhf.2143","article-title":"The heart failure association atlas: heart failure epidemiology and management statistics 2019","volume":"23","author":"Seferovi\u0107","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2022102605495389800_ehac103-B33","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1001\/jamacardio.2019.4987","article-title":"Patient perceptions and familiarity with medical therapy for heart failure","volume":"5","author":"Samsky","year":"2020","journal-title":"JAMA Cardiol"},{"key":"2022102605495389800_ehac103-B34","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1001\/jamacardio.2019.2276","article-title":"Impediments to implementing guideline-directed medical therapies","volume":"4","author":"Fonarow","year":"2019","journal-title":"JAMA Cardiol"},{"key":"2022102605495389800_ehac103-B35","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0140-6736(11)61215-4","article-title":"Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey","volume":"378","author":"Yusuf","year":"2011","journal-title":"Lancet"},{"key":"2022102605495389800_ehac103-B36","doi-asserted-by":"crossref","first-page":"e292","DOI":"10.1016\/S2214-109X(18)30031-7","article-title":"Inequalities in the use of secondary prevention of cardiovascular disease by socioeconomic status: evidence from the PURE observational study","volume":"6","author":"Murphy","year":"2018","journal-title":"Lancet Glob Health"},{"key":"2022102605495389800_ehac103-B37","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0140-6736(15)00469-9","article-title":"Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data","volume":"387","author":"Khatib","year":"2016","journal-title":"Lancet"},{"key":"2022102605495389800_ehac103-B38","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1016\/S0140-6736(18)30802-X","article-title":"Practice patterns and outcomes after stroke across countries at different economic levels (INTERSTROKE): an international observational study","volume":"391","author":"Langhorne","year":"2018","journal-title":"Lancet"},{"key":"2022102605495389800_ehac103-B39","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1161\/CIRCULATIONAHA.120.053291","article-title":"The affordability of guideline-directed medical therapy: cost sharing is a critical barrier to therapy adoption","volume":"143","author":"Sandhu","year":"2021","journal-title":"Circulation"},{"key":"2022102605495389800_ehac103-B40","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s10741-011-9268-9","article-title":"The determinants of clinical outcome and clinical response to CRT are not the same","volume":"17","author":"Cleland","year":"2012","journal-title":"Heart Fail Rev"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/43\/23\/2224\/46636011\/ehac103.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/43\/23\/2224\/46636011\/ehac103.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T01:56:33Z","timestamp":1666749393000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/43\/23\/2224\/6564923"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,8]]},"references-count":40,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2022,4,8]]},"published-print":{"date-parts":[[2022,6,14]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehac103","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,6,14]]},"published":{"date-parts":[[2022,4,8]]}}}